- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TD Cowen initiates Alamar Biosciences stock with buy rating | 1 | Investing.com | ||
| Di | JPMorgan initiates Alamar Biosciences stock with overweight rating | 1 | Investing.com | ||
| Di | Stifel initiates Alamar Biosciences stock with buy rating | 2 | Investing.com | ||
| Fr | Alamar Biosciences, Inc. GAAP EPS of -$1.74, revenue of $26M | 1 | Seeking Alpha | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Fr | Alamar Biosciences, Inc.: Alamar Biosciences Reports First Quarter 2026 Financial Results | 312 | GlobeNewswire (Europe) | FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported... ► Artikel lesen | |
| Fr | Alamar Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Fr | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Cathie Wood Is Buying Up Alamar Biosciences Stock After Its IPO. Should You Snag Proteomics-Focused ALMR Too? | 17 | Barchart.com | ||
| 21.04. | Alamar lists on Nasdaq, giving Qiming its fifth IPO in 2026 | 2 | KrASIA | ||
| 20.04. | Alamar Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 20.04. | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Cathie Wood's Ark Invest buys proteomics company Alamar, Netflix; trims crypto names | 7 | Seeking Alpha | ||
| 20.04. | Qiming Venture Partners: Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ | 428 | PR Newswire | SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ... ► Artikel lesen | |
| 17.04. | Proteomics firm Alamar climbs 40% after upsized IPO | 1 | Seeking Alpha | ||
| 17.04. | Proteomics firm Alamar prices upsized IPO at $17 per share | 1 | Seeking Alpha | ||
| 17.04. | Protein biomarker detection platform Alamar Biosciences prices upsized IPO at $17, the high end of the range | 1 | Renaissance Capital | ||
| 17.04. | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | 536 | AFX News | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| 15.04. | Alamar Biosciences, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 14.04. | Alamar, Hemab, Kailera, and Seaport advance IPOs | - | pharmaphorum | ||
| 13.04. | Protein biomarker detection platform Alamar Biosciences sets terms for $150 million IPO | 1 | Renaissance Capital |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,800 | +2,27 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | +0,35 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +68,52 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +3,56 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| MODERNA | 45,405 | +1,11 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | -0,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,400 | +6,60 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 16,170 | +0,12 % | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | ||
| ARCUTIS BIOTHERAPEUTICS | 20,700 | -2,54 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| BIONTECH | 79,70 | +0,63 % | BioNTech zieht Konsequenzen nach höherem Verlust: Vier Werke dicht | BioNTech hat am Dienstag Zahlen für das erste Quartal 2026 vorgelegt. Das Biotechnologie-Unternehmen aus Mainz erzielte im ersten Quartal 2026 Umsatzerlöse von 118,1 Millionen Euro, nach 182,8 Millionen... ► Artikel lesen | |
| ERASCA | 10,390 | -0,48 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | Evotec im Umbau: Verlust steigt, Strategie-Prüfung läuft | Das Biotech-Unternehmen Evotec erzielte im ersten Quartal 2026 einen Konzernumsatz von 156,6 Millionen Euro, nach knapp 200 Millionen Euro im Vorjahreszeitraum. Der Rückgang erklärt sich nach ANgaben... ► Artikel lesen | |
| NUVALENT | 102,64 | -1,83 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +1,61 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| COGENT BIOSCIENCES | 34,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen |
Das Unternehmen ALAMAR BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 23,050 Euro und damit -3,48 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.